- Home
- COHR vs MRNA Comparison
COHR vs MRNA Comparison
Compare COHR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHR
- MRNA
- Stock Information
- Founded
- COHR 1971
- MRNA 2010
- Country
- COHR United States
- MRNA United States
- Employees
- COHR N/A
- MRNA N/A
- Industry
- COHR Electronic Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COHR Technology
- MRNA Health Care
- Exchange
- COHR Nasdaq
- MRNA Nasdaq
- Market Cap
- COHR 14.3B
- MRNA 16.5B
- IPO Year
- COHR 1987
- MRNA 2018
- Fundamental
- Price
- COHR $95.05
- MRNA $36.85
- Analyst Decision
- COHR Buy
- MRNA Hold
- Analyst Count
- COHR 14
- MRNA 17
- Target Price
- COHR $97.64
- MRNA $87.67
- AVG Volume (30 Days)
- COHR 2.7M
- MRNA 8.4M
- Earning Date
- COHR 11-06-2024
- MRNA 11-07-2024
- Dividend Yield
- COHR N/A
- MRNA N/A
- EPS Growth
- COHR N/A
- MRNA N/A
- EPS
- COHR N/A
- MRNA N/A
- Revenue
- COHR $5,002,740,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- COHR $20.14
- MRNA N/A
- Revenue Next Year
- COHR $11.49
- MRNA N/A
- P/E Ratio
- COHR N/A
- MRNA N/A
- Revenue Growth
- COHR 2.75
- MRNA N/A
- 52 Week Low
- COHR $34.98
- MRNA $35.80
- 52 Week High
- COHR $111.66
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- COHR 45.86
- MRNA 12.62
- Support Level
- COHR $102.51
- MRNA $41.54
- Resistance Level
- COHR $111.66
- MRNA $56.70
- Average True Range (ATR)
- COHR 5.12
- MRNA 2.95
- MACD
- COHR -0.49
- MRNA -1.05
- Stochastic Oscillator
- COHR 20.34
- MRNA 4.80
About COHR Coherent Corp.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.